Testing for genetic predisposition to venous thrombosis
|
|
- Barrie Cole
- 6 years ago
- Views:
Transcription
1 Testing for genetic predisposition to venous thrombosis By Marisa B. Marques, M.D. CONTINUING EDUCATION To earn CEUs, see test on page 20. LEARNING OBJECTIVES Upon completion of this article the reader will be able to: 1. Describe the inherited genetic defects associated with thrombosis. 2. Define the mechanisms and clinical manifestations for hypercoagulability. 3. Describe testing used to evaluate hypercoagulable states. 4. Define the laboratorian s role in providing guidance to physicians for cost-effective testing for patients with thrombosis. CE test published through an educational grant from 8 January 2002 MLO
2 VENOUS THROMBOSIS When the German pathologist Rudolf Virchow postulated more than a century ago that venous thrombosis occurred as a consequence of a triad of factors: stasis of the blood, vessel injury, and/or hypercoagulability, he was unaware of genetic predisposing conditions associated with the latter. Amazingly, his postulate is still true, and several discoveries of the last decade have continued to confirm his observations. This discussion will focus on the genetic abnormalities that can be detected in the laboratory and predispose a patient to develop venous thrombosis. From the start, it is important to emphasize that, when put in perspective, many more patients have acquired rather than inherited risk factors for thrombosis. Furthermore, the former are often stronger than the genetic conditions. It is the combination of genetic and acquired, temporary or permanent, thrombotic risk factors that increases a person s chance to develop thrombotic clinical manifestations. 1 Understanding of synergistic effect of risk factors underlies the need for a complete evaluation, both clinical and in the laboratory. Overview of the discoveries Until 1993, only three genetic defects that predisposed to venous thromboembolism had been identified. These were deficiencies of antithrombin (1965) 2, protein C (1981) 3, or protein S (1984). 4,5 Combined, these phenotypes have been found in only 7.9 percent of unselected patients with venous thrombosis. 6 In 1993, a group of Swedish scientists published a newly discovered hypercoagulability condition that was named Activated Protein C Resistance or APCR. 7 A year later, the underlying defect leading to the phenotypic manifestation of APCR was described as a mutation in the coagulation factor V gene. This was named Factor V Leiden 8, which was found in as much as 10 percent of the population of some European countries, and in 5 percent of Caucasians in the United States. 9,10 Since 1995, high plasma level of factor VIII has also been known to predispose to thrombosis. 11,12 Although its genetic basis has not been confirmed, it is most probably an inherited condition. In 1996, a point mutation in the prothrombin gene that is associated with hypercoagulability was described by Poort, et al. 13 With the ability to test thrombosis patients for the presence of so many new risk factors, many more cases of spontaneous thrombosis can now be at least partially explained. However, since the prevalence of these abnormalities is much higher in Caucasians than in people of any other ethnic background, many events remain unexplained Amid so much information, there is great opportunity for laboratory personnel to elucidate which tests are appropriate for individual patients and when in their clinical presentation they should be performed. Mechanisms of hypercoagulability The mechanisms involved in thrombosis development induced by genetic risk factors discovered so far can be summarized in two groups: 6 1) Decreased control of thrombin generation: activated protein C resistance (due to Factor V Leiden or other causes), prothrombin mutation (20210), elevated factor VIII level, and deficiencies of proteins C and S; or 2) Decreased neutralization of thrombin: antithrombin deficiency. These conditions can also be classified based on their prevalence as seen in Table 1. Clinical manifestations suggestive of venous hypercoagulability There is no difference between the clinical manifestation of venous thrombosis in patients who have inherited versus acquired predisposing conditions. Deep vein thrombosis, especially of the lower extremities, is the most common manifestation of venous thrombophilia. However, the degree of suspicion for a genetic tendency for thrombosis increases when: 1) The thrombotic episode appears to be spontaneous ; 2) There is a history of recurrent episodes; 3) There is a family history of venous thrombosis; 4) The event occurs in a patient younger than years of age; or 5) The thrombosis occurs in an unusual site. Am J Hum Genet 63: , 1998 Table 1: Genetic causes of venous thrombosis Common Activated protein C resistance (APCR)/ Factor V Leiden Prothrombin mutation Methylenetetrahydrofolate reductase gene mutation Increased factor VIII activity Rare Deficiencies of antithrombin and proteins C and S Very Rare Dysfibrinogenemia Risk factor assessment versus diagnostic test An important distinction between the majority of the tests offered by a clinical laboratory and those for assessment of hypercoagulability is the purpose of the information. Results of thrombophilia tests aid in the determination of prognosis Continues on page 10 MLO January
3 COVER STORY Table 2 Acquired conditions affecting functional hypercoagulability test results This color-flow Doppler ultrasound shows a vein with a noncompressible filling defect (arrow) consistent with deep-vein thrombosis. for long-term planning rather than for modification of current patient management. Although much has been discussed in terms of clinical significance of the presence of genetic hypercoagulability defects, the jury is still out. The odds ratio for the development of thrombosis varies amongst the different conditions discovered so far. 16 Protein S deficiency Antithrombin APCR Factor VIII Homocysteine Protein C Protein S Decreased in heparin use, recent thrombosis, liver disease, DIC 1, nephrotic syndrome First generation assays: High factor VIII level, LA 2, acute phase response Second generation assays: Strong LA 2, pregnancy Elevated in acute phase reaction; falsely decreased in the presence of LA 2 Elevated in recent thrombosis, B12, folate, and B6 deficiencies, renal failure, hypothyroidism, medications such as methotrexate, phenytoin, or theophyline, malignancy, pregnancy, menopause Decreased in warfarin therapy, recent thrombosis, surgery, DIC 1, liver disease, vitamin K deficiency, or L-asparaginase therapy; Decreased in warfarin therapy, pregnancy, oral contraceptives or hormone replacement therapy, acute phase reaction, liver dysfunction, proteinuria, vitamin K deficiency, active thrombosis, DIC 1, recent surgery, or L- asparaginase therapy 1 Disseminated intravascular coagulation 2 Lupus anticoagulant 10 January 2002 MLO
4 VENOUS THROMBOSIS confers the highest relative risk, 10 17, followed by Factor V Leiden 18 and protein C deficiency 19 at 7, antithrombin 20, 5, and the prothombin mutation, 13 with a ratio of 2. For the most part, asymptomatic people are not evaluated unless there are circumstances that make the information critical for the prevention of complications. An example of that would be the relative of a Factor V Leiden carrier who is subjected to acquired prothrombotic situations such as pregnancy or prolonged immobilization. In these individuals, the knowledge of a genetic thrombophilic state will most likely affect management and followup. Another reason for testing would be to predict risk of thrombosis recurrence. Independent of the demonstration of a known hypercoagulability risk factor, however, all patients who have had venous thrombosis are prone to have a recurrent event. 6 Furthermore, patients who have antithrombin, protein C or protein S deficiencies, multiple inherited risk factors, or homozygosity for Factor V Leiden, were found to have increased risk of recurrence compared with patients without them Regarding factor VIII, Kyrle has demonstrated that patients with levels at or above the 90 th percentile are at increased risk of recurrence than those below the 90 th percentile. 25 Based on these findings, patients who harbor one or more of these risks are candidates for more prolonged anticoagulation following a thrombotic event. However, the decision to proceed is dependent on a number of other clinical factors that affect the risk-benefit ratio of long-term anticoagulation. The uniqueness of risk factor assessment rather than diagnostic testing affects the way a laboratory operates. Turnaround time is secondary in this arena and should be accommodated to drive costs and labor down. When offering any of the tests described here, it is perfectly reasonable to let physicians know that the assays are batched and performed only a few times a week depending on demand. In our institution, since we started this policy, we have had significant savings each year. How to test for hypercoagulability defects Even when physicians know which conditions to investigate in their thrombosis patients, the laboratory should still provide guidance. The main reasons for the laboratory involvement include the large number of factors that affect the different assays (Table 2) as well as the importance of cost-effective testing. An excellent set of algorithms prepared by Laposata and Van Cott was recently published in CAP Today. 26 The following paragraphs will describe the consensus regarding which tests to order, combined with our experience in saving resources in the performance of these assays. Continues on page 12 Circle 10 for more information. MLO January
5 COVER STORY Antithrombin and proteins C and S deficiencies The initial evaluations for these states are functional assays available from various manufacturers. Normal results rule out deficiencies of these natural anticoagulants and preclude the need for further testing. Abnormal results have to be investigated thoroughly since deficiencies can be secondary to current medical conditions or therapeutic agents such as warfarin and heparin (Table 2). If no explanation exists for the low functional level of these proteins, their plasma concentration should be measured in an immunologic assay. In type I deficiency, both antigen and activity are proportionally low, and in type II deficiency, there is normal antigen but decreased activity (qualitative defect). Protein S deficiency can also be of type III, in which free protein S antigen is low but total protein S antigen is normal. Laboratories performing these assays can also save considerable resources by running the samples in singles rather than in duplicate, providing that validation of this practice is completed and documented. Our policy includes repeating the determinations only in those samples that yield results below the reference range. Table 3: Appropriate tests for the investigation of venous thrombosis Patients on heparin, warfarin or recent thrombosis (< 7 days): Anticardiolipin antibodies APC Resistance (functional test for Factor V Leiden) Prothrombin mutation Patients NOT on anticoagulation > 10 days: Anticardiolipin antibodies Lupus anticoagulant APC Resistance (functional test for Factor V Leiden) Prothrombin mutation Factor VIII Protein C Protein S Antithrombin Homocysteine Activated protein C resistance and Factor V Leiden The screening test for Factor V Leiden is a modification of the functional assay described in 1993 by Dahlbäck et al. 7 The name describes the phenotype conferred by the mutation in factor V, activated protein C resistance (APCR), and it is available as first and second generation assays. In the first generation assay, the patient s plasma is mixed with a contact activator and Ca ++ with or without activated protein C (APC), and the time to clot is determined. In normal individuals, clotting should be at least twice as prolonged in the reaction containing APC compared with that without APC (APCR ratio > 2.0). In this assay system, however, high factor VIII activity, lupus anticoagulant, or factor deficiencies (such as induced by warfarin) can produce an abnormally low APCR ratio in addition to Factor V Leiden. The second generation assay was developed to be more specific for Factor V Leiden by diluting the patient s plasma 1:5 in Factor V-deficient plasma prior to the addition of the reagents. The modified assay also contains polybrene to inactivate heparin. Abnormal APCR ratios in the second generation assay are almost diagnostic of Factor V Leiden and a genetic test for the demonstration of the mutation should be performed to check for zygosity (homozygous versus heterozygous carriers). This determination can be done by polymerase chain reaction (PCR), or the Invader or the microarray technologies. In our experience, strong lupus anticoagulants and pregnancy may still lead to falsely low APCR ratios. A year ago, we adopted a policy of performing the APCR assay as a screening step in all samples with an order for Factor V Leiden. Only those samples that have an abnormally low ratio are referred for genetic testing. Based on the number of orders and the costs of the two tests, we calculate monthly savings of $2,467on average, compared with what it would cost to perform only genetic tests. This is a legitimate comparison because data gathered before we started this intervention showed that more than 90 percent of the orders were for Factor V Leiden instead of APCR and that only 5 percent of the tests were abnormal. Of interest, we have seen exceptional acceptance of this policy by our staff physicians, an example of cost-effectiveness that everyone understands and agrees to. Prothrombin Since there is no screening test for this mutation, whenever clinically indicated it should be investigated by molecular techniques. Of note, carriers have increased prothrombin activity, but this finding is not specific or sensitive enough to be used as a diagnostic tool. 13 Increased factor VIII activity The presence of this hypercoagulability risk factor is assessed by a functional factor VIII assay classically performed in the evaluation and/or management of hemophilia. Although this test is readily available in many clinical laboratories, it is not to be ordered indiscriminately and the result should be interpreted with caution. This is because factor VIII, as an acute phase reactant, increases in many physiologic and pathologic 12 January 2002 MLO
6 VENOUS THROMBOSIS conditions (Table 3). For this reason, assessment of its baseline value may be difficult. If the result is high, it is advisable that it be measured again in different circumstances to check for persistence of the elevation. An alternative approach is to correlate the factor VIII level with that of C-reactive protein, fibrinogen, or erythrocyte sedimentation rate as surrogate markers of acute phase response. Despite much discussion, consensus has not been reached on how to interpret high factor VIII activity. Hyperhomocysteinemia and the C677T mutation in the Methylenetetrahydrofolate reductase (MTHFR) gene We recommend measuring a fasting homocysteine level as the first test in the investigation of abnormalities of this pathway. If the level is elevated, it could be the result of several other causes besides the genetic alteration (Table 2). Furthermore, since the treatment for hyperhomocysteinemia is the same independent of its cause, we do not recommend the genetic test. For the determination of plasma levels of homocysteine, the specimen has to be centrifuged within one hour of collection to avoid artificially elevated level following leakage from blood cells. Dysfibrinogenemia Qualitative abnormalities of fibrinogen can be a risk factor for thrombosis as well as bleeding. This condition can be inherited or acquired, the latter being commonly associated with endstage liver disease. Independent of the cause, dysfibrinogenemia is diagnosed by determination of the plasma concentration of fibrinogen and a functional test such as thrombin or reptilase time. When there is a discrepancy between antigen and activity of fibrinogen, dysfibrinogenemia is diagnosed. How can the laboratory aid physicians in hypercoagulability testing? In the computer system used by our physicians to place laboratory orders, we created links to lists of tests for thrombophilia investigation. Two lists describe the appropriate tests for a patient with a current thrombotic event and/or warfarin or heparin treatment, or for an asymptomatic patient who is also off anticoagulants (Table 3). In the former situation, only a few tests will yield interpretable and meaningful results. In someone with a remote personal or family history of thrombosis, the complete workup is indicated. Physicians can access the lists in the computer screen where the coagulation laboratory tests are displayed, in a separate section designated Hypercoagulability/Thrombosis. Alternatively, the lists can be found in the alphabetical list of tests, under the letters H for hypercoagulability or T for thrombosis. Physicians have to then choose the tests they want from the lists, which are only guides to proper laboratory utilization. Since the implementation of this system, we have seen improvement in the appropriateness of testing for thrombophilia in our hospital. In summary, genetic hypercoagulability risk testing is a dynamic area where discoveries are fast accumulating, offering the laboratory a great opportunity to enhance physician awareness and education. l Dr. Marques is a member of the Department of Pathology, University of Alabama at Birmingham, Birmingham, Al. References 1. Rosendaal FR: Venous thrombosis: a multicausal disease. Lancet 353: , Egeberg O: Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 13: , Griffin JH, Evatt B, Zimmerman TS Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68: , Comp PC, Esmon CT: Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 311: , Schwartz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood 64: , Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 344: , Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90: , Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64-67, Holm J, Zoller B, Berntorp E, Erhardt L, Dahlback B. Prevalence of Factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Inter Med 239: , Ridker PM, Miletich JP, Hennekens CH, Buring GE. Ethnic distribution of Factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 277: , Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345: , O Donnell J, Tuddenham EGD, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 77: , Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated prothrombin levels and an increase in venous thrombosis. Blood 88: , Gregg JP, Yamane AJ, and Grody WW. Prevalence of the Factor V Leiden mutation in four distinct american ethnic populations. Am J Med Genet 73: , Rosendaal FR, Doggen CLM, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of G to A prothrombin variant. Thromb Haemost 79: , Nguyen A. Prothrombin G20210A polymorphism and thrombophilia. Mayo Clin Proc 75: , Heijboier H, Brandjes DPM, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep vein thrombosis. N Engl J Med 323: , Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden. Blood 85: , Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, Conkie JA, Bertina RM. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 73:87-93, Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RW. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 87: , Van den Belt AG, Sanson BJ, Simioni P, Prandoni P, Buller HR, Girolami A, Prins MH. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 157: , Emmerich J, Alhence-Gelas M, Aillaud MF, Juhan-Vague I, Jude B, Garcin JM, Dreyfus M, de Moerloose P, Le Querrec A, Priollet P, Berruyer M, Vallantin X, Wolf M, Aiach M, Fiessinger JN. Clinical features in 36 patients homozygous for the ARG 506- GLN Factor V mutation. Thromb Haemost 77: , Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, Bayliss P, Peake IR, Miller GJ. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 78: , De Stefano V, Martinelli I, Manucci PM, Paciaroni K, Chiusolo P, Casorelli I, Rossi E, Leone G. The risk of recurrent deep venous thrombosis among heterozygous carriers of both Factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 341: , Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Wolfgang S, Lechner K, Eichinger S. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl JMed 343: , Laposata M and Van Cott EM. How to work up hypercoagulability. CAP Today 14:24-26, MLO January
DEEP VENOUS THROMBOSIS AMONG CARRIERS OF FACTOR V LEIDEN AND THE G20210A PROTHROMBIN MUTATION
DEEP VENOUS THROMBOSIS AMONG CARRIERS OF FACTOR V LEIDEN AND THE G20210A PROTHROMBIN MUTATION THE RISK OF RECURRENT DEEP VENOUS THROMBOSIS AMONG HETEROZYGOUS CARRIERS OF BOTH FACTOR V LEIDEN AND THE G20210A
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationThe etiology, diagnosis and treatment of venous thromboembolism Kraaijenhagen, R.A.
UvA-DARE (Digital Academic Repository) The etiology, diagnosis and treatment of venous thromboembolism Kraaijenhagen, R.A. Link to publication Citation for published version (APA): Kraaijenhagen, R. A.
More informationTHROMBOPHILIA SCREENING
THROMBOPHILIA SCREENING Introduction The regulation of haemostasis Normally, when a clot occurs, it exactly occurs where it has to be and does not grow more than necessary due to the action of the haemostasis
More informationIn which direction, and how aggressively,
Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Evaluating idiopathic venous thromboembolism: What is necessary, what is not Charles F. S. Locke, MD Johns Hopkins Community
More informationMolecular mechanisms & clinical consequences. of prothrombin mutations. A.J. Hauer
Molecular mechanisms & clinical consequences of prothrombin mutations A.J. Hauer 07-12-2018 Prothrombin & the coagulation cascade Coagulation factor II, thrombin. Prothrombin is synthesized in the liver
More informationG20210A prothrombin gene mutation identified in patients with venous leg ulcers
J.Cell.Mol.Med. Vol 5, No 4, 2001 pp. 397-401 G20210A prothrombin gene mutation identified in patients with venous leg ulcers Gh. Jebeleanu, Lucia Procopciuc * Department of Medical Biochemistry, University
More informationPrevalence and Association of the Factor V Leiden and Prothrombin G20210A in Healthy Subjects and Patients with Venous Thromboembolism
42(4):488-492,2001 CLINICAL SCIENCES Prevalence and Association of the Factor V Leiden and Prothrombin G20210A in Healthy Subjects and Patients with Venous Thromboembolism Désirée Coen, Renata Zadro, Lorena
More informationThursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III
REGULATION OF COAGULATION Introduction HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Coagulation necessary for maintenance of vascular integrity Enough fibrinogen to clot all vessels
More informationRECURRENT VENOUS THROMBOEMBOLISM AND MUTATION IN THE GENE FOR FACTOR V
THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH AN Arg 506 Gln MUTATION IN THE GENE FOR FACTOR V (FACTOR V LEIDEN) PAOLO SIMIONI, M.D., PAOLO PRANDONI, M.D., PH.D., ANTHONIE W.A. LENSING,
More informationReceived 26 November 1996; accepted for publication 10 February 1997 RAPID PAPER
British Journal of Haematology, 1997, 97, 233 238 RAPID PAPER Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral
More informationShould Patients with Venous Thromboembolism Be Screened for Thrombophilia?
REVIEW Should Patients with Venous Thromboembolism Be Screened for Thrombophilia? James E. Dalen, MD, MPH University of Arizona, Tucson. ABSTRACT In the mid-19th century, Virchow identified hypercoagulability
More informationThrombosis. By Dr. Sara Mohamed Abuelgasim
Thrombosis By Dr. Sara Mohamed Abuelgasim 1 Thrombosis Unchecked, blood coagulation would lead to dangerous occlusion of blood vessels if the protective mechanisms of coagulation factor inhibitors, blood
More informationLaboratory Markers in the Diagnosis of Venous Thromboembolism
Laboratory Markers in the Diagnosis of Venous Thromboembolism Joseph A. Caprini, MD, Catherine J. Glase, BS, Christopher B. Anderson, Karen Hathaway, BS Department of Surgery Evanston Northwestern Healthcare,
More informationVenous thrombosis is a cause of considerable morbidity and is often responsible for
An Update on Hypercoagulable Disorders Daniel G. Federman, MD; Robert S. Kirsner, MD REVIEW ARTICLE Venous thrombosis is a cause of considerable morbidity and is often responsible for chronic venous disorders
More informationHeritable thrombophilic disorders have been
Does thrombophilia play an aetiological role in Legg-Calvé-Perthes disease? S. Hayek*, G. Kenet*, A. Lubetsky, N. Rosenberg, S. Gitel, S. Wientroub From Dana Children s Hospital, Tel-Aviv and the Sheba
More informationThe New England Journal of Medicine
The New England Journal of Medicine Medical Progress GENETIC SUSCEPTIBILITY TO VENOUS THROMBOSIS URI SELIGSOHN, M.D., AND AHARON LUBETSKY, M.D. THE annual incidence of venous thrombosis, one of the leading
More informationGenetics. Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A
Genetics Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A Willem M. Lijfering, MD, PhD; Saskia Middeldorp, MD, PhD;
More informationLaboratory Evaluation of Venous Thrombosis Risk
Laboratory Evaluation of Venous Thrombosis Risk Dorothy M. Adcock, MD Volume 17, Number 12 December 2003 Objective: The reader will be able to discuss the concepts of risk factor, risk potential and thrombotic
More informationCombined Effect of Factor V Leiden and Prothrombin 20210A on the Risk of Venous Thromboembolism
2001 Schattauer GmbH, Stuttgart Thromb Haemost 2001; 86: 809 16 Combined Effect of Factor V Leiden and Prothrombin 20210A on the Risk of Venous Thromboembolism Pooled Analysis of 8 Case-control Studies
More informationSession Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD
Thrombosis II Session Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD Inherited Risk Factors for Venous Thrombosis Mary Cushman Venous
More informationConsultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000
Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Dorothy M. (Adcock) Funk, M.D. Karen A. Moser, M.D. Esoterix Coagulation September 20, 2013 Disclosures
More informationResistance to Activated Protein C, Factor V Leiden and the Prothrombin G20210A Variant in Patients with Colorectal Cancer
Pathophysiology of Haemostasis andthrombosis Original Paper Pathophysiol Haemost Thromb 2002;32:2 7 Received: December 8, 2000 Accepted in revised form: August 20, 2001 Resistance to Activated Protein
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationAPC-PCI complex concentration is higher in patients with previous venous thromboembolism with Factor V Leiden.
APC-PCI complex concentration is higher in patients with previous venous thromboembolism with Factor V Leiden. Strandberg, Karin; Stenflo, Johan; Nilsson, C; Svensson, Peter Published in: Journal of Thrombosis
More informationCombined Factor V Leiden and Prothrombin Genotyping in Patients Presenting With Thromboembolic Episodes
Combined Factor V Leiden and Prothrombin Genotyping in Patients Presenting With Thromboembolic Episodes John A. Friedline, MD; Ejaz Ahmad, MD; Diana Garcia, MD; Deborah Blue, MD; Noel Ceniza, MD; Joan
More informationPrevalence of Activated Protein C Resistance in Acute Myocardial Infarction in Japan
Clinical Studies Prevalence of Activated Protein C Resistance in Acute Myocardial Infarction in Japan Kazunori HAYASHI, MD, Takahito SONE,1 MD, Junichiro KONDOH,1 MD, Hideyuki TSUBOI,1 MD, Hiromi SASSA,1
More informationThrombophilia: To test or not to test
Kenneth Bauer, MD Harvard Medical School, Boston, MA Professor of Medicine VA Boston Healthcare System Chief, Hematology Section Beth Israel Deaconess Medical Center, Boston, MA Director, Thrombosis Clinical
More informationHIGH PLASMA LEVELS OF FACTOR VIII AND THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM
HIGH PLASMA LEVELS OF FACTOR VIII AND THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM HIGH PLASMA LEVELS OF FACTOR VIII AND THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM PAUL A. KYRLE, M.D., ERICH MINAR, M.D.,
More informationABC Fax Case Report. D. Gemmati M.L. Serino S. Moratelli S. Tognazzo A. Ongaro G.L.
Case Report Haemostasis 2001;31:99 105 Received: October 10, 2000 Accepted after revision: April 5, 2001 Coexistence of Factor V G1691A and Factor II G20210A Gene Mutations in a Thrombotic Family Is Associated
More informationAfter a first episode of acute venous thromboembolism
Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia Gualtiero
More informationAbnormally Short Activated Partial Thromboplastin Times Are Related to Elevated Plasma Levels of TAT, F1+2, D-Dimer and FVIII:C
Pathophysiology of Haemostasis andthrombosis Original Paper Pathophysiol Haemost Thromb 2002;32:137 142 DOI: 10.1159/000065217 Received: January 28, 2002 Accepted in revised form: June 28, 2002 Abnormally
More informationInherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD
Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis
More informationCOAGULATION INHIBITORS LABORATORY DIAGNOSIS OF PROTHROMBOTIC STATES REGULATION OF. ANTICOAGULANT PROTEIN DEFICIENCY Disease entities COAGULATION
LABORATORY DIAGNOSIS OF PROTHROMBOTIC COAGULATION INHIBITORS Tissue Factor Pathway Inhibitor (TFPI) Lipoprotein Associated Coagulation Inhibitor (LACI) Extrinsic Pathway Inhibitor (EPI) Complexes with
More informationVenous Thrombosis: Prevalence and Interaction of Risk Factors
Main Paper Haemostasis 1999;29(suppl 1)1-9 Venous Thrombosis: Prevalence and F.R. Rosendaal Umversity Hospital Leiden, Leiden, The Netherlands KeyWords Gene-gene interaction Gene-environment interaction
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Prothrombin 20210A A Mild Risk Factor for Venous Thromboembolism but Not for Arterial Thrombotic Disease and Pregnancy-Related Complications in a Family Study Ivan Bank, MD, PhD;
More informationCEREBRAL-VEIN THROMBOSIS ASSOCIATED WITH A PROTHROMBIN-GENE MUTATION AND ORAL-CONTRACEPTIVE USE
CEREBRAL-VEIN ASSOCIATED WITH A PROTHROMBIN-GENE MUTATION AND ORAL-CONTRACEPTIVE USE HIGH RISK OF CEREBRAL-VEIN IN CARRIERS OF A PROTHROMBIN-GENE MUTATION AND IN USERS OF ORAL CONTRACEPTIVES IDA MARTINELLI,
More informationImpact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A
Journal of Thrombosis and Haemostasis, 2: 430 436 ORIGINAL ARTICLE Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A
More informationLUP. Lund University Publications Institutional Repository of Lund University
LUP Lund University Publications Institutional Repository of Lund University This is an author produced version of a paper published in Journal of thrombosis and thrombolysis. This paper has been peer-reviewed
More informationThrombophilia. Menno V. Huisman, MD, and Frits Rosendaal, MD
Thrombophilia Menno V. Huisman, MD, and Frits Rosendaal, MD Thrombophilia is now considered a multicausal disease, with an interplay of acquired and genetic risk factors. Recent studies have shown that
More informationN ATT. The Genetics of Thrombophilia. Written by: Elizabeth Varga, M.S.*
N ATT The National Alliance for Thrombosis and Thrombophilia The Genetics of Thrombophilia Written by: Elizabeth Varga, M.S.* Edited by: Amy Sturm, M.S., CGC* *Genetic Counselor, The Adult Medical Genetics
More informationDiagnosis and management of heritable thrombophilias
Link to this article online for CPD/CME credits Diagnosis and management of heritable thrombophilias Peter MacCallum, 1 2 Louise Bowles, 2 David Keeling 3 1 Wolfson Institute of Preventive Medicine, Barts
More informationPhD, Mesut DEMIR, 1. MD, Mustafa DEMIRTAS, Murat ÇAYLI, 1 MD, Cumhur ALHAN, 1 MD, and Fikri BASLAMISLI,
Experimental Studies Prothrombin 20210GA and Factor V Leiden Mutations in Patients Less Than 55 Years Old With Myocardial Infarction Yurdaer DÖNMEZ, 1 MD, Mehmet KANADASI, 1 MD, Kahraman TANRIVERDI, 2,3
More informationThe prothrombin gene variant 20210A in venous and arterial thromboembolism
Haematologica 1999; 84:356-362 molecular basis of disease The prothrombin gene variant 20210A in venous and arterial thromboembolism VICENTE VICENTE, ROCIO GONZÁLEZ-CONEJERO, JOSÉ RIVERA, JAVIER CORRAL
More informationOriginal Policy Date
MP 2.04.71 Genetic Testing for Inherited Thrombophilia Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search12:2013 Return to
More informationProthrombin G20210A Gene Mutation and Further Prothrombotic Risk Factors in Childhood Thrombophilia
Prothrombin G20210A Gene Mutation and Further Prothrombotic Risk Factors in Childhood Thrombophilia Ralf Junker, Hans-Georg Koch, Karin Auberger, Nicole Münchow, Silke Ehrenforth, Ulrike Nowak-Göttl, for
More informationOptimal Utilization of Thrombophilia Testing
Optimal Utilization of Thrombophilia Testing Rajiv K. Pruthi, MBBS Special Coagulation Laboratory & Comprehensive Hemophilia Center Division of Hematology/Internal Medicine Dept of Laboratory Medicine
More informationThe Multi-Factorial Threshold Model of Thrombotic Risk
The Multi-Factorial Threshold Model of Thrombotic Risk Richard A. Marlar, PhD and Dorothy M. Adcock, MD The incidence of venous thrombosis in the US is between two and three million per year, resulting
More informationThe risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study
Journal of Thrombosis and Haemostasis, 12: 635 640 DOI: 10.1111/jth.12528 ORIGINAL ARTICLE The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study
More informationTHROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO
THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO DISCLAIMER I m a pediatrician I will be discussing this issue primarily from a pediatric perspective
More informationGenetics of Arterial and Venous Thrombosis: Clinical Aspects and a Look to the Future
Genetics of Arterial and Venous Thrombosis: Clinical Aspects and a Look to the Future Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular
More informationGenetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수
Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?
More informationThrombophilia and Venous Thromboembolism: Implications for Testing
Thrombophilia and Venous Thromboembolism: Implications for Testing Danny M. Cohn, M.D., 1 Sara Roshani, M.D., 1 and Saskia Middeldorp, M.D., Ph.D. 2 ABSTRACT In the last decades, the knowledge on the etiology
More informationChapter. A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families
Chapter A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families Willem M. Lijfering Nic J.G.M. Veeger Saskia Middeldorp Karly Hamulyák Martin
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/37409 holds various files of this Leiden University dissertation Author: Engbers, Marissa Title: Conventional and age-specific risk factors for venous thrombosis
More informationThe New England Journal of Medicine HIGH LEVELS OF COAGULATION FACTOR XI AS A RISK FACTOR FOR VENOUS THROMBOSIS
HIGH LEVELS OF COAGULATION FACTOR XI AS A RISK FACTOR FOR VENOUS THROMBOSIS JOOST C.M. MEIJERS, PH.D., WINNIE L.H. TEKELENBURG, M.SC., BONNO N. BOUMA, PH.D., ROGIER M. BERTINA, PH.D., AND FRITS R. ROSENDAAL,
More informationArterial Ischemic Stroke with Protein S Deficiency in Pakistan
Case Reports Arterial Ischemic Stroke with Protein S Deficiency in Pakistan Faika Usman, Ali Hassan, Arsalan Ahmad From Section of Neurology, Department of Medicine, Shifa International Hospitals and College
More informationHypercoagulability can be defined as the tendency to have thrombosis as a result of
Hypercoagulability Syndromes Robert H. Thomas, MD REVIEW ARTICLE Hypercoagulability can be defined as the tendency to have thrombosis as a result of certain inherited and/or acquired molecular defects.
More informationGenetic Approach to Thrombophilia
Thromb Haemost 2001; 86: 92 103 2001 Schattauer GmbH, Stuttgart Genetic Approach to Thrombophilia Rogier M. Bertina Hemostasis and Thrombosis Research Center, Department of Haematology, Leiden University
More informationJOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH How to cite this article: CHOWTA NITHYANANDA K, ARUN S, BIPIN P, FAZIL A. CHRONIC THROMBOEMBOLIC PULMONARY ARTERY HYPERTENSION WITH DEEP VEIN THROMBOSIS DUE
More informationTHE INCIDENCE RATE OF A FIRST
ORIGINAL CONTRIBUTION Thrombophilia, Clinical Factors, and Recurrent Venous Thrombotic Events Sverre C. Christiansen, MD Suzanne C. Cannegieter, MD, PhD Ted Koster, MD, PhD Jan P. Vandenbroucke, MD, PhD
More informationEVALUATION OF FACTOR VIII AS A RISK FACTOR FOR DEEP VEIN THROMBOSIS
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Khalid A. Mahmood Volume 3, Issue 3, 103-110. Research Article ISSN 2278 4357 EVALUATION OF FACTOR VIII AS A RISK FACTOR FOR DEEP Article Received
More informationHaplotypes of VKORC1, NQO1 and GGCX, their effect on activity levels of vitamin K-dependent coagulation factors, and the risk of venous thrombosis
Haplotypes of VKORC1, NQO1 and GGCX, their effect on activity levels of vitamin K-dependent coagulation factors, and the risk of venous thrombosis Haplotypes of VKORC1, NQO1 and GGCX, their effect on activity
More informationScott M. Stevens, MD. Co-Director, Thrombosis Clinic. Associate Professor of Clinical Medicine
Scott M. Stevens, MD Co-Director, Thrombosis Clinic Intermountain Medical Center Associate Professor of Clinical Medicine The University of Utah School of Medicine No Relevant Financial Relationships Research
More informationI CI =confidence interval
Prothrombin G20210A Polymorphism and Thrombophilia ADRIAN NGUYEN, MD Recently, a single mutation in the 3'-untranslated region of the prothrombin gene was reported, resulting in a G-to-A substitution.
More informationComparison of Three Methods for Measuring Factor VIII Levels in Plasma
Coagulation and Transfusion Medicine / THREE FACTOR VIII ASSAYS Comparison of Three Methods for Measuring Factor VIII Levels in Plasma Wayne L. Chandler, MD, Chris Ferrell, MT(ASCP), Joo Lee, MT(ASCP),
More informationImproved Distinction of Factor V Wild-Type and Factor V Leiden Using a Novel Prothrombin-Based Activated Protein C Resistance Assay
Coagulation and Transfusion Medicine / A NOVEL PROTHROMBIN-BASED APC-R ASSAY Improved Distinction of Factor V Wild-Type and Factor V Leiden Using a Novel Prothrombin-Based Activated Protein C Resistance
More informationThrombosis Research 105 (2002) Brief Communication
Thrombosis Research 105 (2002) 49 53 Brief Communication Recurrent pulmonary embolism in a 13-year-old male homozygous for the prothrombin G20210A mutation combined with protein S deficiency and increased
More informationChoosing Wisely: If, When, What, and Who to Test for Thrombophilia
Choosing Wisely: If, When, What, and Who to Test for Thrombophilia Nicole Dodge Zantek, MD, PhD Medical Director, Special Coagulation Laboratory University of Minnesota Disclosures Financial interests
More informationVenous thromboembolism (VTE) consists of deep vein
Clinical Utility of Factor V Leiden (R506Q) Testing for the Diagnosis and Management of Thromboembolic Disorders Richard D. Press, MD, PhD; Kenneth A. Bauer, MD; Jody L. Kujovich, MD; John A. Heit, MD
More informationARTICLE IN PRESS. Thrombophilia Testing in Patients with Venous Thrombosis. Feinberg School of Medicine, Chicago, IL, USA UNCORRECTED PROOF
Eur J Vasc Endovasc Surg xx, 1 6 (xxxx) doi:10.1016/j.ejvs.2005.05.034, available online at http://www.sciencedirect.com on 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
More informationCausative factors of deep vein thrombosis of lower limb in Indian population
International Surgery Jthisnal Khadilkar R et al. Int Surg J. 18 Jan;(1):3-3 http://www.ijsurgery.com pissn 39-33 eissn 39-9 Original Research Article DOI: http://dx.doi.org/1.183/39-9.isj17919 Causative
More informationThe Risk of Recurrent Venous Thromboembolism in Men and Women
The new england journal of medicine original article The Risk of Recurrent Venous Thromboembolism in Men and Women Paul A. Kyrle, M.D., Erich Minar, M.D., Christine Bialonczyk, M.D., Mirko Hirschl, M.D.,
More informationProtein C and protein S levels can be accurately determined within 24 hours of diagnosis of acute venous thromboembolism
Clin. Lab. Haem. 2006, 28, 9 13 M. J. KOVACS*, J. KOVACS*, J. ANDERSON, M. A. RODGER, K. MACKINNON, P. S. WELLS Summary Keywords Protein C and protein S levels can be accurately determined within 24 hours
More informationFactor V Leiden and The Risk of Pulmonary Embolism
Review Article Factor V Leiden and The Risk of Pulmonary Embolism Shrestha Mukesh, Li Wei * Department of Pulmonary and Critical Care, The First Affiliated Hospital of Kunming Medical University, Kunming,
More informationThrombophilia testing in patients with venous thrombosis
Thrombophilia testing in patients with venous thrombosis Joseph A. Caprini, MD, Sofia Goldshteyn, MD, Catherine J. Glase, BS, Karen Hathaway, BS, Evanston and Chicago, IL. Department of Surgery Evanston
More informationUpper-extremity deep vein thrombosis (DVT) is a rare
Vascular Medicine Risk Factors and Recurrence Rate of Primary Deep Vein Thrombosis of the Upper Extremities Ida Martinelli, MD, PhD; Tullia Battaglioli, MD; Paolo Bucciarelli, MD; Serena Maria Passamonti,
More informationCerebral sinus-venous thrombosis (CSVT) is a rare disease
Vascular Medicine Long-Term Evaluation of the Risk of Recurrence After Cerebral Sinus-Venous Thrombosis Ida Martinelli, MD, PhD; Paolo Bucciarelli, MD; Serena M. Passamonti, MD; Tullia Battaglioli, MD;
More informationAdvances in understanding pathogenic mechanisms of thrombophilic disorders
ASH 50th anniversary review Advances in understanding pathogenic mechanisms of thrombophilic disorders Björn Dahlbäck 1 1 Department of Laboratory Medicine, Section of Clinical Chemistry, Lund University,
More informationChapter. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy
Chapter Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy Willem M. Lijfering Min Ki ten Kate Herman G. Sprenger Jan van der Meer
More informationThe diagnosis and clinical manifestations of activated protein C resistance: a case report and review of the literature
Vascular Medicine 1996; 1: 275-280 The diagnosis and clinical manifestations of activated protein C resistance: a case report and review of the literature Howard Daniel Hoerl", Aldo Tabares" and Kandice
More informationDISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University
Thrombophilia! DISCLOSURE Presented by: Merav Sendowski, MD Oregon Health and Science University Created by: Thomas Deloughery, MD Oregon Health and Science University Current Relevant Financial Relationship(s)
More informationPolymorphisms in the protein C gene as risk factor for venous thrombosis
CHAPTER 6 Polymorphisms in the protein C gene as risk factor for venous thrombosis Pomp ER, Doggen CJM, Vos HL, Reitsma PH, Rosendaal FR. Accepted for publication in Thrombosis and Haemostasis Chapter
More informationAre there still any valid indications for thrombophilia screening in DVT?
Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016
More informationRecurrent Venous Thrombo-Embolism in a Young Adult Female: Case Report with Review of Literature
Cronicon OPEN ACCESS CARDIOLOGY Case Report Recurrent Venous Thrombo-Embolism in a Young Adult Female: Case Report with Review of Literature Ehab M Esheiba 1 *, Ani Purushothaman 2 1 Departments of Cardiology,
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationThe factor V Leiden mutation: Spectrum of thrombotic events and laboratory evaluation
The factor V Leiden mutation: Spectrum of thrombotic events and laboratory evaluation Franklin A. Bontempo, MD, Andrea Cortese Hassett, PhD, Hawazin Faruki, DrPH, David L. Steed, MD, Marshall W. Webster,
More informationHemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures
Hemostasis PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Disorders of Hemostasis - Hemophilia - von Willebrand Disease HEMOPHILIA A defect in the thrombin propagation phase
More informationThrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE
LA APLA 1 3 ACA Anti-ß2-GP I 2 45 Thrombophilia Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC GASCO Atlanta Sept 8 th, 2017 Disclosures Conflicts of interest: NONE Off-label product use discussion:
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism
More informationElevated Plasma Factor VIII and d-dimer Levels as Predictors of Poor Outcomes of Thrombosis in Children
The new england journal of medicine original article Elevated Plasma Factor VIII and d-dimer Levels as Predictors of Poor Outcomes of Thrombosis in Children Neil A. Goldenberg, M.D., R. Knapp-Clevenger,
More informationFactor V Leiden Mutation and Other Thrombophilia Markers in Childhood Ischemic Stroke
Clin Appl Thrombosis/Hemostasis 11(1):83 88, 2005 2005 Westminster Publications, Inc., Glen Head, NY Factor V Leiden Mutation and Other Thrombophilia Markers in Childhood Ischemic Stroke Rıdvan Duran,
More informationThrombophilia testing: who is it good for? F.R. Rosendaal, Leiden
Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden Inaugural meeting of Iranian Society on Thrombosis and Haemostasis Mofid Children Hospital Tehran, 24 December 2015 Chest. 2012;141(2_suppl):e48S-e801S
More informationRetinal vein occlusion and factor V Leiden and prothrombin G:A mutations
European Journal of Ophthalmology / Vol. 11 no. 4, 2001 / pp. 351-355 Retinal vein occlusion and factor V Leiden and prothrombin 20210 G:A mutations S. ARAS 1, G. YILMAZ 2, İ. ALPAS 1, V. BALTACI 1, E.
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationDeterminants of the APTT- and ETP-based APC sensitivity tests
Journal of Thrombosis and Haemostasis, 3: 1488 1494 ORIGINAL ARTICLE Determinants of the APTT- and ETP-based APC sensitivity tests M. C. H. DE VISSER,* A. VAN HYLCKAMA VLIEG,* G. TANS,à J. ROSING,à A.
More informationCLINICAL FELLOWSHIP PROGRAM IN COAGULATION
CLINICAL FELLOWSHIP PROGRAM IN COAGULATION The Department of Pathology and Laboratory Medicine University of Alberta, Faculty of Medicine and Dentistry and Alberta Health Services CLINICAL FELLOWSHIP IN
More informationThrombophilia due to Activated Protein C Resistance
CASE REPORT JIACM 2005; 6(3): 244-7 Thrombophilia due to Activated Protein C Resistance Kamal S Saini*, Mrinal M Patnaik*, Vidya S Nagar**, Alaka K Deshpande*** Abstract Thrombophilia is a hereditary or
More information